Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client. The value of the contract is £55k and it is expected to complete in this calendar year.
Click here to read in full....
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that based on its current unaudited accounts at 20th June, it is trading ahead of market expectations for its full financial year ending 30th June 2018.
Click here to read in full...
Physiomics consultant and senior advisor, Dr David Orrell, will give one of the keynote speeches at the 38th International Symposium on Forecasting, Colorado USA on 17th June. The conference is the premiere international event focused on forecasting across a spectrum of social and scientific disciplines.
The event is organised by the International Institute of Forecasters (IIF), which promotes best practices and advancing the field of forecasting through...
Physiomics is pleased to announce that following feedback from clients and shareholders it has today updated its website at https://www.physiomics.co.uk/. In its recent placing announcement of the 23 May 2018, the Company stated its intention to improve its marketing approach, and the launch of the new site is a small but important step towards executing this goal. Features of the upgraded site include:
Fresher, cleaner...
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has completed a placing, conditional only on Admission, to raise £525,000.00 (gross) from the issue of 13,125,000 new ordinary shares of 0.4p each ("Ordinary Shares") at a price of 4.0p per share, through Hybridan LLP (the "Placing"). Application...
Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction.
Please click here to watch video....
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a new UK based biotech client. The value of the contract is £48k and it is expected to complete in this calendar year.
Click here to read in full....
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it will attend BioTrinity 2018. BioTrinity is one of Europe’s leading biopartnering and investment conferences, to be held on 23-25 April at the Novotel London West.
Click here to read more....
The Company announces that it received notice today that Dr Chassagnole (COO) transferred paper share certificates of 121,522 shares and 265,111 shares to his nominee account ‘Interactive Investor Services Nominees Limited’.
Click here to read in full...